Saad Z. Usmani, MD, MBA, FACP, on the Latest in Multiple Myeloma Research

This article was originally published on Cancer Network

Treatment options for multiple myeloma only continued to improve over the course of 2020, even with the development of the coronavirus disease 2019 (COVID-19) pandemic.

Advancements such as the approval of selinexor (Xpovio) in combination with bortezomib (Velcade) and dexathamethasone for the treatment of adults with multiple myeloma who have received at least 1 prior therapy, as well as ongoing research presented at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition demonstrated the progress that is being made for this disease.

In an interview with CancerNetwork®, Saad Z. Usmani, MD, MBA, FACP, division chief of Plasma Cell Disorders and director of Clinical Research in Hematological Malignancies at Levine Cancer Institute, discussed the ongoing research in multiple myeloma and the ongoing research that he believes could possibly shape multiple myelomathe future of systemic therapy treatment in 2021.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences channels.

To continue reading this article on Cancer Network